Abstract
Department of Clinical Viro-Immunology, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, and Laboratory of Experimental and Clinical Immunology, University of Amsterdam, Amsterdam, The Netherlands The natural course of HIV-I infection is highly variable between individuals. Therefore, surrogate markers, alone or in combination, have been extensively evaluated for their ability to predict progression to disease. With the increasing opportunities for early intervention with antiviral drugs, there is a growing need for surrogate markers that can be used as inclusion/exclusion criteria and for monitoring the clinical course during treatment. Moreover, early markers that predict long term clinical efficacy of the drug administered are needed to decide on continuation or modification of therapy. In addition, the availability of such surrogate markers may limit the study period and number of participants in clinical trials without decreasing statistical power to unreliably low levels. This brief review provides an overview of the most commonly used surrogate markers for monitoring HIV-I infection and discusses the available data on their predictive value in the outcome of antiviral therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
